| Name | Title | Contact Details |
|---|
Blaze Bioscience, Inc. is a privately held biotechnology company focused on guided therapies. Blaze was founded in 2010 by Dr. Jim Olson, a pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center and Seattle Children`s Hospital, and Heather Franklin, a former senior business executive from ZymoGenetics. Blaze is working to develop Tumor Paint products and Optide*-based guided therapeutics.
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery.
Cerno Bioscience is a company that develops and publishes mass spectrometry calibration and analysis software that extends the limits of mass spectrometry.
Cancer Genetic Consultants is a Leawood, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999. Genmab`s ordinary shares are publicly traded on Nasdaq Copenhagen and American Depositary Shares under its ADR Program are listed in the United States on the Nasdaq Global Select Market. Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates (ADCs), bispecific antibodies created from our DuoBody® technology platform, and antibodies created with our HexaBody® technology.